{"links":{"html":"https://www.erudio.com/reports/alpacca-nct07185997","json":"https://www.erudio.com/reports/alpacca-nct07185997.json","markdown":"https://www.erudio.com/reports/alpacca-nct07185997.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"alpacca-07185997"}},"request":"https://www.erudio.com/contact?report=alpacca-07185997"},"offer":{"cited_commentary_sources":5,"verified_hcp_statements":13,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":3,"optional":true,"price_per_verified_person_usd":15,"price_usd":45,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"alpacca-nct07185997"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=alpacca-07185997","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/alpacca-nct07185997","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-01T15:14:35.584359Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":7,"no_commentary_found":4},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Progression Free Survival (PFS) determined by blinded independent central review (BICR)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Confirmed overall response rate (ORR) as determined by BICR"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":0,"title":"Secondary endpoints"},{"claim_count":6,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":5,"title":"Population and setting"},{"claim_count":2,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":1,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T6","registry_field":"outcomesModule","source_count":0,"title":"Safety and tolerability"},{"claim_count":4,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":3,"coverage":"discussed","id":"A1","source_count":3,"title":"Earlier prospective activity—not ALPACCA results"},{"claim_count":1,"coverage":"discussed","id":"A2","source_count":1,"title":"Stage-specific development and the global-approval question"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":2,"title":"Prospective response-and-resistance research"},{"claim_count":1,"coverage":"discussed","id":"A4","source_count":1,"title":"Unmet need and chemotherapy-free positioning"}],"counts":{"cited_sources":5,"claims_by_expression_type":{"experience":2,"interpretation":3,"opinion":5,"question":1,"restatement":1,"unspecified":1},"claims_by_kind":{"source_observation":13},"clinician_statements":11,"evidence_units":7,"findings":4,"organisational_accounts":1,"people_cited":3,"people_identity_verified":3,"people_total":3,"screened_sources":12,"verified_claims":13},"findings_index":[{"id":"F1","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":0},"has_counterview":false,"limitations":2,"links":{"context":0,"support":1},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Ou raises a conditional global-approval question—not an ALPACCA failure report"},{"id":"F2","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":2,"questions":0,"restated":1,"views":2},"has_counterview":false,"limitations":3,"links":{"context":3,"support":5},"ma_question":true,"named_voices":3,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Earlier efficacy signals and comparator attributes are background—not ALPACCA results"},{"id":"F3","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":1,"views":4},"has_counterview":false,"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":4,"passages":4,"sources":4,"sources_by_kind":{"commentary":4}},"title":"The dedicated randomized program is welcomed as progress toward mutation-specific care"},{"id":"F4","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":4},"ma_question":true,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Le presents resistance research and collaboration as the next development step"}],"medical_affairs_question":"What can Medical Affairs say about ALPACCA's development and treatment-option rationale without turning earlier activity signals or a cross-setting approval question into an ALPACCA conclusion?","sections":{"analysis":[{"id":"section-1","level":2,"title":"A conditional approval question must stay separate from ALPACCA's outcome"},{"id":"section-2","level":2,"title":"Activity signals and option-specific attributes are not comparative proof"},{"id":"section-3","level":2,"title":"Dedicated PACC evidence attracts enthusiasm, with different source positions"},{"id":"section-4","level":2,"title":"Resistance research is anticipated, not completed"},{"id":"section-5","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Progression Free Survival (PFS) determined by blinded independent central review (BICR)"},{"findings":[],"id":"T2","label":"Primary endpoint: Confirmed overall response rate (ORR) as determined by BICR"},{"findings":[],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":4}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":2}],"id":"T5","label":"The comparison"},{"findings":[],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F3","shared_claims":4}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-01T15:14:35.584359Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-01T15:22:40Z","record_hash":"2db9edcb1fe0cc0123557ec1ec5cf83588c972e95b957575a795fb6d0c7b14a7","release_hash":"1bb154d22fb807d48536d1616c2d4a1d42b4589d71929e24b1a8aaf70a46e271","report_id":"erudio-nct07185997","run_id":"ccbbab0f-8f6c-4517-8d95-77d2c0ad7f8a","schema_version":"5.0","slug":"alpacca-07185997","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"ALPACCA compares first-line firmonertinib with osimertinib or afatinib in locally advanced or metastatic EGFR PACC-mutant NSCLC; commentary includes a conditional global-approval question, not an ALPACCA failure report. The report cites two medical oncologists, one described in the source as involved in ALPACCA. Further discussion asks why dedicated randomized PACC evidence is welcomed and how earlier activity signals should be interpreted. What can Medical Affairs say about development and treatment options without turning those signals or cross-setting approval questions into ALPACCA conclusions?","meta_description":"12 sources screened · 13 verified statements (11 from clinicians verified by NPI or staff page) from 5 sources · 4 findings. Updated Nov 1, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-44e95272b2145c15b820"],"id":"F1","paraphrase":"An X post asks about the possibility of global approval across disease settings.","publication_caveats":{"reason":"Publication-specific caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"x_thread","source_date":"2026-10-07","title":"Ou raises a conditional global-approval question—not an ALPACCA failure report"}]},"publication":{"approved_at":"2026-11-01T15:22:40Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":12},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","6 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits apply, so some matching discussion may be missing.","Discussion centered on ALPACCA and its registry names may miss relevant views expressed without those names or with other wording.","Some passages were not fully assessed for clinician views, so the report is not a complete account of the clinical decision or public discussion.","Repeated posts and reposts do not establish independent agreement or the prevalence of a view.","Le is described in the source as involved in ALPACCA; this is source-described involvement, not an independently confirmed trial role.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The earlier efficacy studies are not named in the relevant posts. Their populations, assessment details and comparability cannot be reconstructed from these statements.","No full protocol or results publication for the exact trial was available in the sources reviewed. Regulatory labels matching the intervention names as searched were not identified; that absence does not establish lack of approval.","The sources provide no ALPACCA efficacy or safety outcome, no comparative CNS estimate and no answer to the global-approval question."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":4,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":5},"count":5,"evidence_window":{"end":"2026-10-07","start":"2025-12-04"},"retrieval_snapshot":"2026-11-01T14:46:40.436530Z","timeline":[{"count":2,"week":"2025-W49"},{"count":1,"week":"2025-W52"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W41"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT07185997:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07185997:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ixhbdqjpmxzmvg44pleup2ah-3malmeislhk25","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kwntu4mgap2otpkyzq5bchim-3malcoxliw627","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7402154858880892928","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1997356334061146185:09e2e798-9139-4260-bbf0-ca2d7dd54773","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2003088644601479608:b66444e2-ed3e-4805-b1b1-6a32576894cb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2003090124394119567:83ec1dbb-695a-4a1b-8d15-0614fb47bb8e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2003133324752277756:134910e4-ffbc-4bd8-a26a-6dd940f8ed15","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2003134423487939018:912a9587-bab1-45b6-9575-a2020b874029","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060432749543260311:ba5a1c79-7157-462b-89b0-9cfd1fbc21e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060432920066838957:5be010c5-3eae-4ec3-bc53-e3eafe7bb11b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2067591919081766941:f72d65bd-1d75-40f8-8362-bb06a0e0e804","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2107641752353976541:ec7d3020-62eb-43c5-9776-ffa463432743","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":2,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":9,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":12},"count":12,"evidence_window":{"end":"2026-10-07","start":"2025-12-04"},"retrieval_snapshot":"2026-11-01T14:46:40.436530Z","timeline":[{"count":2,"week":"2025-W49"},{"count":6,"week":"2025-W52"},{"count":2,"week":"2026-W22"},{"count":1,"week":"2026-W25"},{"count":1,"week":"2026-W41"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: firmonertinib","status":"unmapped"},{"reason":"Unmapped registry intervention: egfr-tki inhibitor based on investigator's choice","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"},{"reason":"Unmapped registry condition: EGFR P-Loop and Alpha C-Helix Compressing","status":"unmapped"},{"reason":"Unmapped registry condition: EGFR PACC","status":"unmapped"},{"reason":"Unmapped registry condition: EGFR Uncommon Mutations","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"ALPACCA","aliases":["ALPACCA","Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations","A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)"],"brief_title":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-Small-Cell Lung Cancer","Metastatic Non-Small-Cell Lung Cancer","Advanced Non-Small-Cell Lung Cancer","EGFR P-Loop and Alpha C-Helix Compressing","EGFR PACC","EGFR Uncommon Mutations"],"display_condition":"first-line locally advanced or metastatic EGFR PACC NSCLC","display_interventions":[["firmonertinib"]],"enrollment":{"count":480,"type":"ESTIMATED"},"interventions":[{"name":"Firmonertinib","synonyms":["AST2818"],"type":"DRUG"},{"name":"EGFR-TKI inhibitor based on investigator's choice","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT07185997","official_title":"A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2029-02","type":"ESTIMATED"},"primary_endpoints":[{"description":"PFS is defined as the time from randomization to the first occurrence of disease progression as determined by BICR using RECIST v1.1, or death from any cause, whichever occurs first.","measure":"Progression Free Survival (PFS) determined by blinded independent central review (BICR)","timeFrame":"Until progression or death, assessed up to approximately 4 years"},{"description":"Confirmed ORR is defined as the percentage of participants with a confirmed CR or PR based on BICR assessment relative to the total number of participants.","measure":"Confirmed overall response rate (ORR) as determined by BICR","timeFrame":"Until progression or death, assessed up to approximately 3 years"}],"registered_date":{"date":"2025-09-22","type":"ACTUAL"},"registry_last_updated":"2026-10-14","registry_url":"https://clinicaltrials.gov/study/NCT07185997","short_name":"ALPACCA","short_name_basis":"canonical_name","sponsor":"ArriVent BioPharma, Inc.","start_date":{"date":"2025-12-17","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"FURMO-006","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}